159 related articles for article (PubMed ID: 32088783)
21. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.
Li D; Zhang Y; Xie Y; Xiang J; Zhu Y; Yang J
Cancer Gene Ther; 2013 Apr; 20(4):251-9. PubMed ID: 23470565
[TBL] [Abstract][Full Text] [Related]
22. [Gene therapy with tumor suppressor gene p53 and(or) p16 on the nude mice models of NSCLC in vivo].
Wu W; Zhang X; Qi X
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jul; 23(7):403-5. PubMed ID: 11778504
[TBL] [Abstract][Full Text] [Related]
23. Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).
Yang F; Shi P; Xi X; Yi S; Li H; Sun Q; Sun M
Med Oncol; 2006; 23(2):191-204. PubMed ID: 16720919
[TBL] [Abstract][Full Text] [Related]
24. Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo.
Xande JG; Dias AP; Tamura RE; Cruz MC; Brito B; Ferreira RA; Strauss BE; Costanzi-Strauss E
Gene Ther; 2020 Feb; 27(1-2):51-61. PubMed ID: 31439890
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
26. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.
Guan YS; Liu Y; Zou Q; He Q; La Z; Yang L; Hu Y
J Zhejiang Univ Sci B; 2009 May; 10(5):331-40. PubMed ID: 19434759
[TBL] [Abstract][Full Text] [Related]
28. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.
Nishizaki M; Meyn RE; Levy LB; Atkinson EN; White RA; Roth JA; Ji L
Clin Cancer Res; 2001 Sep; 7(9):2887-97. PubMed ID: 11555607
[TBL] [Abstract][Full Text] [Related]
29. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
Mi J; Zhang X; Rabbani ZN; Liu Y; Reddy SK; Su Z; Salahuddin FK; Viles K; Giangrande PH; Dewhirst MW; Sullenger BA; Kontos CD; Clary BM
Mol Ther; 2008 Jan; 16(1):66-73. PubMed ID: 17912235
[TBL] [Abstract][Full Text] [Related]
30. p53 tumor suppressor gene therapy for cancer.
Roth JA; Swisher SG; Meyn RE
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):148-54. PubMed ID: 10550840
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo.
Zhang H; Sui A; Wang Z; Liu S; Yao R
Int J Mol Med; 2012 Aug; 30(2):358-64. PubMed ID: 22614533
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation.
Nishikawa T; Ramesh R; Munshi A; Chada S; Meyn RE
Mol Ther; 2004 Jun; 9(6):818-28. PubMed ID: 15194048
[TBL] [Abstract][Full Text] [Related]
34. Highly Expressed FOXF1 Inhibit Non-Small-Cell Lung Cancer Growth via Inducing Tumor Suppressor and G1-Phase Cell-Cycle Arrest.
Wu CY; Chan CH; Dubey NK; Wei HJ; Lu JH; Chang CC; Cheng HC; Ou KL; Deng WP
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370197
[TBL] [Abstract][Full Text] [Related]
35. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
36. MDM2 knockdown mediated by a triazine-modified dendrimer in the treatment of non-small cell lung cancer.
Huang Q; Li L; Li L; Chen H; Dang Y; Zhang J; Shao N; Chang H; Zhou Z; Liu C; He B; Wei H; Xiao J
Oncotarget; 2016 Jul; 7(28):44013-44022. PubMed ID: 27259273
[TBL] [Abstract][Full Text] [Related]
37. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
Gu L; Deng ZJ; Roy S; Hammond PT
Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
[No Abstract] [Full Text] [Related]
38. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene.
Inoue A; Narumi K; Matsubara N; Sugawara S; Saijo Y; Satoh K; Nukiwa T
Cancer Lett; 2000 Aug; 157(1):105-12. PubMed ID: 10893449
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
40. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin.
Roth JA
Hum Gene Ther; 1996 May; 7(8):1013-30. PubMed ID: 8727511
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
